Metabolic
Retatrutide
CLINICAL DEVELOPMENTInvestigational · Phase 3 · Not FDA-approved
OVERVIEW
Retatrutide is an experimental metabolic medicine designed to activate three hormone receptors involved in appetite, blood-sugar regulation, digestion, and energy balance. It has produced large average weight reductions in human trials, but it remains investigational and is not FDA-approved.
RESEARCH CONTEXT
Researchers are interested because retatrutide combines GIP, GLP-1, and glucagon receptor activity in one molecule. The glucagon component may add effects on energy expenditure and liver-fat metabolism beyond dual incretin agonism.
MECHANISM & BIOLOGY
Retatrutide is a triple agonist at the GIP receptor, GLP-1 receptor, and glucagon receptor. GIP and GLP-1 signaling influence glucose-dependent insulin secretion, appetite, gastric function, and central satiety. Glucagon receptor signaling affects hepatic metabolism, lipid handling, and energy expenditure. The balance among these pathways is central to the compound’s experimental design.
HUMAN RESEARCH
Phase 2 randomized trials in obesity reported dose-dependent reductions in body weight over 48 weeks, with mean reductions exceeding 20% in higher-dose groups. Trials in type 2 diabetes also reported improvements in glycemic measures and body weight. Multiple Phase 3 studies are ongoing, including obesity, cardiovascular, kidney, osteoarthritis, and head-to-head programs.
PRECLINICAL RESEARCH
Preclinical work helped establish the rationale for combining incretin and glucagon receptor signaling and suggested effects on energy expenditure, glucose control, and lipid metabolism. Human trials now provide substantially stronger evidence than the original animal program.
SAFETY DATA
Human trials have reported gastrointestinal adverse events typical of incretin-based therapies, including nausea, diarrhea, vomiting, and decreased appetite. Heart-rate increases have also been observed. Long-term safety remains under evaluation in Phase 3 development.
EVIDENCE GAPS
Retatrutide has not completed the FDA approval process. Long-term cardiovascular, pancreatic, gallbladder, thyroid, and other safety outcomes require continued study. Results from clinical-trial material do not establish the identity, purity, safety, or equivalence of products sold outside authorized trials.
RELATED COMPOUNDS / DISTINCTIONS
Tirzepatide activates GIP and GLP-1 receptors. Retatrutide adds glucagon receptor agonism, making it a triple-receptor investigational compound.
Back to compound list ↑
Metabolic
Tirzepatide
FDA-APPROVED ACTIVE INGREDIENTFDA-approved in specific prescription products
OVERVIEW
Tirzepatide is a dual GIP and GLP-1 receptor agonist. FDA-approved prescription products containing tirzepatide are used for type 2 diabetes, chronic weight management, and certain additional labeled indications. It has one of the strongest human evidence bases in this library.
RESEARCH CONTEXT
Tirzepatide demonstrated that targeting two incretin pathways at the same time could produce strong effects on glucose regulation, appetite, and body weight. It also became an important comparison point for newer multi-receptor compounds such as retatrutide.
MECHANISM & BIOLOGY
Tirzepatide activates the GIP and GLP-1 receptors. These receptors influence glucose-dependent insulin release, glucagon regulation, satiety signaling, food intake, and gastric emptying. Tirzepatide is engineered for prolonged activity and is pharmacologically distinct from single-receptor GLP-1 agonists.
HUMAN RESEARCH
Large randomized SURPASS and SURMOUNT programs demonstrated clinically meaningful reductions in HbA1c and body weight. FDA-approved products include Mounjaro for type 2 diabetes and Zepbound for chronic weight management. Zepbound also has an FDA-approved indication involving moderate-to-severe obstructive sleep apnea in adults with obesity.
PRECLINICAL RESEARCH
Animal and receptor studies established dual GIP/GLP-1 activity before large clinical programs. At this point, human randomized evidence is much more informative for approved uses than preclinical findings.
SAFETY DATA
FDA labeling includes gastrointestinal adverse effects, gallbladder disease, pancreatitis warnings, acute kidney injury related to volume depletion, and a boxed warning concerning thyroid C-cell tumors observed in rats. Hypoglycemia risk increases when used with certain glucose-lowering medications.
EVIDENCE GAPS
Approval applies to specific FDA-reviewed finished drug products, formulations, manufacturing controls, and labeled uses. It does not establish equivalence of independently sourced material. Long-term outcomes continue to be studied across cardiometabolic disease.
RELATED COMPOUNDS / DISTINCTIONS
Semaglutide primarily targets GLP-1. Tirzepatide targets GIP plus GLP-1. Retatrutide adds glucagon receptor agonism to those two pathways.
Back to compound list ↑
Tissue Biology
KLOW
COMPONENT-LEVEL EVIDENCEFour-component blend · Blend itself not clinically validated
OVERVIEW
KLOW is a blend of GHK-Cu, BPC-157, TB-500, and KPV. Those ingredients are studied for different aspects of tissue biology, inflammation, extracellular-matrix remodeling, and cell migration. The important distinction is that research on the individual ingredients is not the same as evidence for the combined blend.
RESEARCH CONTEXT
The blend brings together four research themes: copper-peptide signaling, experimental tissue-repair pathways, thymosin-related cell migration, and melanocortin-derived inflammatory signaling.
MECHANISM & BIOLOGY
GHK-Cu interacts with copper-dependent tissue-remodeling pathways. BPC-157 has been studied in animal injury models involving angiogenesis, nitric-oxide signaling, fibroblasts, and tendon healing. TB-500 is a short thymosin-beta-4 fragment associated with actin biology; published regenerative research more commonly examines full thymosin beta-4. KPV is an alpha-MSH-derived tripeptide studied for inflammatory and epithelial signaling.
HUMAN RESEARCH
There is no robust clinical-trial evidence validating KLOW as a four-component combination. Human evidence differs sharply by ingredient and route. GHK-Cu has dermatologic and tissue-remodeling literature, while BPC-157, TB-500 fragment, and KPV lack adequate human clinical evidence for commonly promoted systemic uses.
PRECLINICAL RESEARCH
The majority of repair claims associated with the blend come from animal, cell, or ex vivo studies of the individual components. Those studies explore tendon, wound, intestinal, skin, inflammatory, angiogenic, and extracellular-matrix biology.
SAFETY DATA
A combination creates additional uncertainty because interactions, pharmacokinetics, immunogenicity, and aggregate exposure have not been characterized in controlled human trials. FDA has specifically identified limited safety information for BPC-157, injectable GHK-Cu, KPV, and the TB-500 thymosin-beta-4 fragment in the compounding context.
EVIDENCE GAPS
There is no established evidence that combining the four ingredients creates additive or synergistic clinical benefit. Safety and effectiveness of the blend as a whole remain uncharacterized.
RELATED COMPOUNDS / DISTINCTIONS
KLOW should not be treated as interchangeable with Wolverine. Wolverine focuses on BPC-157 plus TB-500, while KLOW additionally contains GHK-Cu and KPV.
Back to compound list ↑
Endocrine
CJC-1295 / Ipamorelin
EARLY HUMAN + MECHANISTICNot FDA-approved · Important formulation differences
OVERVIEW
CJC-1295 and ipamorelin are growth-hormone secretagogue research compounds that act through different receptors. CJC-related molecules mimic growth-hormone-releasing hormone signaling, while ipamorelin activates the ghrelin receptor. The combination is discussed because the two pathways converge on growth-hormone release.
RESEARCH CONTEXT
Researchers study whether combining hypothalamic GHRH-type signaling with ghrelin-receptor signaling changes the timing or magnitude of growth-hormone secretion. The growth-hormone axis is also closely linked with sleep physiology, especially deep slow-wave sleep.
MECHANISM & BIOLOGY
CJC-1295-related compounds act at the GHRH receptor on pituitary somatotrophs. Ipamorelin is a selective agonist at the growth-hormone secretagogue/ghrelin receptor. Both pathways can stimulate pulsatile growth-hormone release and downstream IGF-1 signaling. Published human CJC-1295 studies primarily involve the long-acting DAC form; that evidence should not be automatically transferred to “No DAC” formulations.
HUMAN RESEARCH
Small human studies of long-acting CJC-1295 showed prolonged increases in growth hormone and IGF-1 while preserving pulsatile secretion. Human ipamorelin studies demonstrated dose-related GH release. These studies were not large outcome trials for body composition, recovery, or sleep disorders.
PRECLINICAL RESEARCH
Mechanistic and animal studies support receptor selectivity and GH-secretagogue activity. Ipamorelin was developed for greater GH selectivity relative to some earlier secretagogues.
SAFETY DATA
FDA has cited limited clinical data for CJC-1295 and reports including increased heart rate and systemic vasodilatory reactions. FDA also identifies immunogenicity and characterization concerns for ipamorelin and notes serious adverse events in an intravenous gastrointestinal-motility study. Long-term safety of the commonly marketed combination is not established.
EVIDENCE GAPS
There is no FDA-approved CJC-1295/ipamorelin combination, and no strong evidence that the combination treats insomnia or improves sleep quality. Normal physiology does show that a major GH pulse occurs shortly after sleep onset in association with slow-wave sleep, but that relationship does not prove a sleep-treatment effect from these compounds.
RELATED COMPOUNDS / DISTINCTIONS
CJC-1295 is not the same as tesamorelin. Tesamorelin is an FDA-approved GHRH analogue for a specific HIV-associated indication. CJC-1295 DAC and CJC “No DAC” also differ materially in pharmacokinetics.
Back to compound list ↑
Endocrine
Tesamorelin
FDA-APPROVED ACTIVE INGREDIENTFDA-approved for a specific HIV-associated indication
OVERVIEW
Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone. An FDA-approved prescription product uses tesamorelin to reduce excess abdominal visceral fat in adults with HIV-associated lipodystrophy. It is not approved as a general weight-loss drug.
RESEARCH CONTEXT
Tesamorelin provides a clinically validated example of stimulating the body’s own growth-hormone axis rather than administering growth hormone directly. Research has focused on visceral adipose tissue, GH/IGF-1 physiology, liver fat, and metabolic effects in HIV-associated lipodystrophy.
MECHANISM & BIOLOGY
Tesamorelin binds the GHRH receptor on pituitary somatotroph cells and stimulates endogenous pulsatile growth-hormone secretion. Growth hormone then increases hepatic and peripheral IGF-1 signaling and influences lipolysis, protein metabolism, and body-composition physiology.
HUMAN RESEARCH
Randomized controlled trials supporting approval showed reductions in visceral adipose tissue in adults with HIV-associated lipodystrophy. Additional studies have investigated liver fat and metabolic endpoints. The approved indication is specifically reduction of excess abdominal fat in HIV-associated lipodystrophy.
PRECLINICAL RESEARCH
Preclinical endocrinology established GHRH receptor activity and GH-axis effects. Because substantial human evidence exists for the approved indication, animal findings are less central to understanding clinical use.
SAFETY DATA
Known concerns include increased IGF-1, glucose intolerance or diabetes risk, fluid retention, hypersensitivity, and injection-site reactions. The approved labeling includes contraindications and cautions related to malignancy, pregnancy, and pituitary/hypothalamic axis disruption.
EVIDENCE GAPS
Evidence for HIV-associated lipodystrophy should not be generalized to routine weight loss, bodybuilding, “anti-aging,” or sleep treatment. Effects outside the approved population and indication require separate evidence.
RELATED COMPOUNDS / DISTINCTIONS
Tesamorelin is a GHRH analogue with an FDA-approved indication. CJC-1295 is an investigational GHRH-related compound with a different evidence and regulatory profile.
Back to compound list ↑
Tissue Biology
Wolverine (BPC-157 / TB-500)
PRECLINICALResearch combination · Not FDA-approved
OVERVIEW
“Wolverine” is a research-market name for a BPC-157 and TB-500 combination. Most claims around the pair come from animal and laboratory work involving tissue repair, tendon healing, angiogenesis, inflammation, and cell migration. Strong controlled human evidence for the combination is not available.
RESEARCH CONTEXT
BPC-157 and thymosin-related peptides are frequently grouped because they influence different parts of experimental repair biology. BPC-157 research often centers on injured connective tissue and gastrointestinal models. Thymosin beta-4 biology centers on actin, cell migration, angiogenesis, and wound repair.
MECHANISM & BIOLOGY
BPC-157 has been reported in preclinical models to influence angiogenic signaling, fibroblast activity, nitric-oxide pathways, collagen organization, and tendon-cell outgrowth. TB-500 is commonly described as a short fragment related to thymosin beta-4; full thymosin beta-4 binds actin and has extensive experimental literature on cell migration and tissue repair. Evidence from full thymosin beta-4 should not automatically be attributed to the TB-500 fragment.
HUMAN RESEARCH
Published human evidence for BPC-157 is extremely limited. FDA states it has identified no or only limited safety information for proposed routes. FDA also states it has not identified human exposure data for the TB-500 thymosin-beta-4 fragment.
PRECLINICAL RESEARCH
Rat Achilles-tendon studies reported accelerated structural and functional healing with BPC-157. Thymosin beta-4 studies have reported accelerated wound healing and increased cell migration in experimental systems. These findings remain preclinical for the commonly sold combination.
SAFETY DATA
Human pharmacokinetics, immunogenicity, long-term safety, carcinogenicity, reproductive safety, and interaction data for the combination are not adequately characterized. Peptide purity and fragment identity also matter when extrapolating from published thymosin-beta-4 research.
EVIDENCE GAPS
There is no controlled evidence establishing that BPC-157 plus TB-500 is superior to either component, and no established human protocol for injury recovery. The “Wolverine” name is a commercial shorthand, not a clinically validated formulation.
RELATED COMPOUNDS / DISTINCTIONS
BPC-157 and TB-500 are biologically distinct. BPC-157 is a 15-amino-acid peptide studied heavily in Croatian preclinical models. TB-500 is a short fragment related to the 43-amino-acid thymosin beta-4 protein.
Back to compound list ↑
Mitochondrial
MOTS-C
PRECLINICAL + ENDOGENOUS HUMAN BIOLOGYResearch compound · No FDA-approved drug
OVERVIEW
MOTS-C is a small peptide encoded by mitochondrial DNA. Researchers study it as a signal that connects mitochondria with whole-body metabolism, stress adaptation, glucose handling, and exercise physiology. Humans naturally produce MOTS-C, but that does not establish the safety or benefit of administering it as a drug.
RESEARCH CONTEXT
MOTS-C is part of a newer field called mitochondrial-derived peptides. These molecules challenge the older idea that mitochondria only make cellular energy by showing that mitochondria also send regulatory signals to the rest of the cell and body.
MECHANISM & BIOLOGY
Experimental studies link MOTS-C to AMPK and cellular energy-sensing pathways, folate/purine metabolism, glucose utilization, stress-response gene expression, and nuclear translocation under metabolic stress. Effects on skeletal-muscle metabolism and mitochondrial adaptation have been explored extensively in mice.
HUMAN RESEARCH
Human observational and physiology studies show that endogenous MOTS-C levels respond to exercise and metabolic conditions. A 2021 study reported exercise-induced MOTS-C expression in human skeletal muscle and circulation. These studies evaluate naturally occurring MOTS-C biology rather than proving therapeutic benefit from exogenous administration.
PRECLINICAL RESEARCH
Mouse studies report improved metabolic homeostasis, insulin sensitivity, exercise capacity, and stress adaptation. Newer mechanistic work continues to investigate AMPK/PGC-1α-linked mitochondrial bioenergetics.
SAFETY DATA
FDA states it has not identified human exposure data for drug products containing MOTS-C and lacks sufficient information to determine safety. Immunogenicity and peptide-characterization concerns remain relevant for compounded or investigational formulations.
EVIDENCE GAPS
Human pharmacokinetics, therapeutic dosing, long-term safety, interaction effects, and clinical efficacy remain undefined. Endogenous exercise-associated changes should not be interpreted as evidence that exogenous MOTS-C reproduces exercise benefits in people.
RELATED COMPOUNDS / DISTINCTIONS
MOTS-C is a mitochondrial-derived signaling peptide. SS-31/elamipretide is a synthetic mitochondria-targeting peptide that binds cardiolipin and now has an FDA-approved finished drug for Barth syndrome.
Back to compound list ↑
Mitochondrial
NAD+
HUMAN BIOLOGY + LIMITED FORMULATION EVIDENCEEndogenous coenzyme · Formulation-specific evidence varies
OVERVIEW
NAD+ is not a peptide. It is an essential coenzyme found in every cell and is central to energy production, redox chemistry, DNA-repair signaling, and cellular stress responses. The biology of NAD+ is well established. The benefits of administering NAD+ itself are much less established.
RESEARCH CONTEXT
NAD+ sits at the intersection of metabolism and cellular maintenance. Interest increased because NAD+ levels and NAD-related pathways change with aging, metabolic stress, inflammation, and many disease states.
MECHANISM & BIOLOGY
NAD+/NADH carries electrons during glycolysis, the citric-acid cycle, and mitochondrial oxidative metabolism. NAD+ is also consumed by sirtuins, PARP DNA-repair enzymes, CD38, and other signaling proteins. This links NAD availability to bioenergetics, DNA repair, calcium signaling, immune biology, and gene regulation.
HUMAN RESEARCH
Human research is much stronger for oral NAD+ precursors such as nicotinamide riboside and NMN than for direct NAD+ administration. A small 2019 infusion study described the plasma and urinary metabolite fate of directly infused NAD+. Newer human infusion studies continue to evaluate tolerability and biomarker effects, but evidence for broad “energy,” “anti-aging,” or performance claims remains limited.
PRECLINICAL RESEARCH
A large preclinical literature links NAD depletion and restoration to mitochondrial function, DNA repair, metabolic health, neurobiology, and aging phenotypes. Translating these findings to specific human NAD+ formulations has been difficult.
SAFETY DATA
Direct NAD+ infusion can be associated with infusion-related discomfort and other adverse symptoms depending on rate and formulation. Long-term clinical safety data for repeated high-dose administration remain limited. FDA has also cited regulatory issues involving compounded NAD+ products under section 503B.
EVIDENCE GAPS
It is not established that raising extracellular or plasma NAD+ produces the same cellular effects as manipulating intracellular NAD metabolism. Clinical outcomes, optimal formulations, routes, and long-term effects remain active research questions.
RELATED COMPOUNDS / DISTINCTIONS
NAD+ is a universal cellular coenzyme. MOTS-C is a mitochondrial signaling peptide. SS-31/elamipretide targets mitochondrial membrane cardiolipin. They are often grouped under “mitochondrial” research but act very differently.
Back to compound list ↑
Inflammation
KPV
PRECLINICALResearch tripeptide · No FDA-approved drug
OVERVIEW
KPV stands for lysine-proline-valine. It is a three-amino-acid fragment of alpha-melanocyte-stimulating hormone, or alpha-MSH. Researchers study KPV mainly for inflammatory signaling, intestinal-barrier biology, skin inflammation, and immune responses.
RESEARCH CONTEXT
KPV is interesting because it appears to retain part of alpha-MSH’s anti-inflammatory biology without carrying the full hormone’s pigment-related activity. Much of the work focuses on the gut and epithelial tissues.
MECHANISM & BIOLOGY
Experimental studies report effects on NF-κB and MAPK inflammatory signaling, cytokine expression, epithelial transport, and immune-cell responses. Intestinal research also suggests uptake through the PepT1 peptide transporter may contribute to local anti-inflammatory effects.
HUMAN RESEARCH
FDA states it has not identified human exposure data for drug products containing KPV administered by any route. There is therefore no established human therapeutic efficacy or safety profile.
PRECLINICAL RESEARCH
Mouse colitis models reported reduced inflammatory infiltrates, myeloperoxidase activity, and disease severity. Cell and drug-delivery studies have explored intestinal epithelial targeting, macrophage biology, mucosal healing, and inflammatory cytokines.
SAFETY DATA
The absence of human exposure data is a major limitation. Immunogenicity, systemic pharmacokinetics, long-term toxicity, reproductive effects, and interactions remain insufficiently characterized.
EVIDENCE GAPS
It is unknown whether the anti-inflammatory effects seen in animal colitis and cell models translate to humans, which disease states would be relevant, or whether systemic exposure is desirable or safe.
RELATED COMPOUNDS / DISTINCTIONS
KPV is a fragment of alpha-MSH focused mainly on inflammatory research. It is unrelated mechanistically to BPC-157, although both are often discussed in gut and tissue-repair communities.
Back to compound list ↑
Cognitive
Semax
EARLY / REGIONAL HUMAN EVIDENCENot FDA-approved in the United States
OVERVIEW
Semax is a synthetic peptide derived from a short ACTH-related sequence. Researchers have studied it for attention, memory, neuroprotection, neuroplasticity, and recovery after neurological injury. Much of the human literature comes from Russia and is smaller or less internationally replicated than evidence for FDA-approved neurologic drugs.
RESEARCH CONTEXT
Semax attracts interest because it appears to influence neurotrophic signaling rather than acting like a traditional stimulant. BDNF, a protein involved in neuronal survival and plasticity, appears repeatedly in the Semax literature.
MECHANISM & BIOLOGY
Semax is commonly described as an ACTH(4-10)-related peptide without the adrenal steroid effects of ACTH. Preclinical studies report changes in BDNF/TrkB signaling, neurotrophin expression, monoaminergic pathways, inflammatory gene expression, oxidative stress, and synaptic plasticity.
HUMAN RESEARCH
Regional clinical studies have investigated Semax in ischemic stroke and rehabilitation. A 2018 study of 110 post-stroke patients reported higher plasma BDNF and improved functional-recovery measures in Semax-treated groups. Such findings are interesting but do not meet the breadth of evidence normally expected for U.S. drug approval.
PRECLINICAL RESEARCH
Rodent and molecular studies report effects on memory, attention, neurotrophic signaling, ischemic injury, inflammation, and stress-response pathways. These studies help define mechanisms but cannot establish clinical effectiveness on their own.
SAFETY DATA
FDA states that compounded Semax may pose immunogenicity risks and that it has no or limited safety information for proposed routes of administration. U.S.-standard long-term safety, interaction, reproductive, and carcinogenicity data are lacking.
EVIDENCE GAPS
It is unclear how well regional clinical findings generalize to broader populations, which mechanisms drive any observed cognitive effects, and whether long-term use changes risk. Semax is not FDA-approved for ADHD, depression, stroke, memory enhancement, or other neurologic conditions.
RELATED COMPOUNDS / DISTINCTIONS
Semax is generally researched around cognitive/neurotrophic signaling. Selank is more commonly researched around anxiety, stress response, and GABA-related mechanisms.
Back to compound list ↑
Cognitive
Selank
EARLY / REGIONAL HUMAN EVIDENCENot FDA-approved in the United States
OVERVIEW
Selank is a synthetic peptide derived from tuftsin, a naturally occurring immune-related peptide fragment. It has been studied mainly for anxiety-related behavior, stress response, emotional regulation, and cognition. The idea is often described as “calm focus,” but the evidence remains limited by U.S. regulatory standards.
RESEARCH CONTEXT
Researchers are interested in whether Selank links nervous-system and immune signaling. Studies have examined GABA-related pathways, enkephalins, neurotrophins, and stress responses rather than a classic sedative mechanism.
MECHANISM & BIOLOGY
Preclinical work explores modulation of GABAergic signaling, enkephalin metabolism, BDNF-related gene expression, monoamine systems, and neuroimmune pathways. The mechanism is not fully defined and likely involves multiple signaling systems.
HUMAN RESEARCH
Small regional studies have evaluated Selank in generalized anxiety and related conditions. One published study reported anxiolytic effects and changes in neurophysiologic measures. These data are not equivalent to large, independently replicated randomized programs.
PRECLINICAL RESEARCH
Animal and gene-expression studies explore anxiety behavior, memory, GABA receptor systems, stress responses, immune signaling, and neuroplasticity.
SAFETY DATA
FDA states that Selank acetate may pose immunogenicity risks and that important human safety information is lacking. Long-term safety, drug interactions, reproductive effects, and standardized pharmacokinetics remain inadequately characterized.
EVIDENCE GAPS
There is no established U.S. indication, no FDA-approved Selank product, and insufficient evidence to conclude that it treats anxiety, depression, insomnia, or cognitive disorders. The extent to which reported regional findings replicate internationally is uncertain.
RELATED COMPOUNDS / DISTINCTIONS
Selank and Semax are both synthetic Russian-developed peptides, but their research emphasis differs. Selank is more associated with anxiety/stress pathways; Semax is more associated with cognition, BDNF, and neuroprotection.
Back to compound list ↑
Tissue Biology
GHK-Cu
LAB + DERMATOLOGIC HUMAN EVIDENCECopper peptide · Injectable safety data limited
OVERVIEW
GHK-Cu is a naturally occurring copper-binding tripeptide made from glycine, histidine, and lysine. It is best known for research involving skin remodeling, collagen-related biology, wound repair, fibroblasts, and extracellular matrix.
RESEARCH CONTEXT
Copper is required by enzymes involved in connective tissue and antioxidant defense. GHK acts as a high-affinity copper carrier and also appears to influence gene expression and tissue-remodeling signals.
MECHANISM & BIOLOGY
GHK-Cu has been reported to influence fibroblast behavior, matrix metalloproteinases, glycosaminoglycan synthesis, collagen-related pathways, angiogenesis, antioxidant signaling, and inflammatory responses. Its effects are highly dependent on tissue, concentration, formulation, and route.
HUMAN RESEARCH
Controlled dermatologic studies and long-standing cosmetic research suggest topical copper-peptide formulations can influence aged-skin appearance and remodeling markers. Human evidence is much stronger for topical/cosmetic contexts than for systemic administration.
PRECLINICAL RESEARCH
Cell and animal models show effects on fibroblasts, endothelial cells, wound healing, extracellular matrix, and gene-expression networks. These findings underpin the peptide’s broad regenerative reputation.
SAFETY DATA
FDA specifically notes limited human data for injectable GHK-Cu and potential immunogenicity/peptide-impurity concerns in compounded injectable products. Safety information from topical cosmetic use should not be assumed to apply to systemic exposure.
EVIDENCE GAPS
The magnitude and clinical relevance of many broad gene-expression claims remain uncertain. Systemic pharmacokinetics, long-term injectable safety, and disease-treatment claims are not established.
RELATED COMPOUNDS / DISTINCTIONS
GHK-Cu and AHK-Cu are both copper-binding tripeptides. GHK-Cu has a broader tissue-remodeling literature, while AHK-Cu has a smaller evidence base with notable hair-follicle research.
Back to compound list ↑
Formulation Research
The Lemon Bottle
INSUFFICIENT RELIABLE EVIDENCEBranded formulation · Regulatory warnings exist
OVERVIEW
Lemon Bottle is a branded product promoted internationally for localized fat reduction. Unlike a defined peptide or an FDA-approved fat-dissolving drug, its published scientific evidence is weak and regulators have raised serious concerns about product composition and authenticity.
RESEARCH CONTEXT
It became popular through social media because it was marketed as a “natural” alternative to established injectable lipolysis products. That popularity has outpaced reliable clinical evidence.
MECHANISM & BIOLOGY
Marketing materials have attributed effects to ingredients such as bromelain, lecithin, riboflavin, pineapple-derived components, and other botanicals. A validated pharmacologic mechanism for the branded product has not been demonstrated through high-quality independent clinical trials.
HUMAN RESEARCH
There are no robust peer-reviewed randomized human trials establishing the branded Lemon Bottle formulation as an effective fat-reduction treatment. Evidence supporting deoxycholic acid injection should not be transferred to Lemon Bottle because they are different products and mechanisms.
PRECLINICAL RESEARCH
Ingredient-level laboratory literature exists for several proposed components, but that does not validate the composition, delivery, safety, or effectiveness of the finished branded product.
SAFETY DATA
Swissmedic tested samples from different sources and reported that declared ingredients did not match laboratory findings; one sample contained only caffeine and another lacked the declared ingredients. Swissmedic stated that no medicinal effect had been scientifically proven and advised against use. Finnish regulators also issued warnings.
EVIDENCE GAPS
Composition consistency, authenticity, sterility, pharmacology, effective ingredients, and clinical safety are uncertain across products sold under the name. This uncertainty is itself one of the most important facts about Lemon Bottle.
RELATED COMPOUNDS / DISTINCTIONS
Deoxycholic acid has FDA-approved use in a specific finished product for submental fat. Lemon Bottle is not deoxycholic acid and should not inherit the evidence or regulatory status of approved deoxycholic-acid products.
Back to compound list ↑
Tissue Biology
AHK-Cu
LAB / EX VIVOResearch copper peptide
OVERVIEW
AHK-Cu is a copper-binding tripeptide made from alanine, histidine, and lysine. Its best-known research area is hair-follicle biology, especially dermal papilla cells that help regulate hair growth.
RESEARCH CONTEXT
AHK-Cu offers a narrower copper-peptide research story than GHK-Cu. It became interesting after experiments suggested effects on human hair follicles and cultured dermal papilla cells.
MECHANISM & BIOLOGY
The exact mechanism is not fully established. Experimental work suggests copper-dependent effects on dermal papilla cell proliferation, growth-factor signaling, and follicular biology. As with other copper peptides, concentration and formulation likely matter substantially.
HUMAN RESEARCH
Evidence includes ex vivo human hair-follicle experiments and cultured human dermal papilla cells rather than large clinical trials. This means the tissue studied was human, but the evidence does not establish clinical effectiveness in people.
PRECLINICAL RESEARCH
Laboratory studies have examined follicle elongation, dermal papilla cell proliferation, and signaling related to hair growth. The overall literature is small.
SAFETY DATA
Robust systemic safety data are lacking. There is no FDA-approved AHK-Cu drug and no well-characterized long-term pharmacokinetic or toxicology program for systemic exposure.
EVIDENCE GAPS
It remains unclear whether laboratory hair-follicle effects translate into meaningful clinical hair growth, which formulation would be required, and how AHK-Cu compares with established hair-loss therapies.
RELATED COMPOUNDS / DISTINCTIONS
AHK-Cu is structurally related to GHK-Cu but is not interchangeable. GHK-Cu has a broader skin/tissue-remodeling literature; AHK-Cu has more focused hair-follicle evidence.
Back to compound list ↑
Metabolic
5-Amino-1MQ
PRECLINICALSmall molecule NNMT inhibitor · Not a peptide
OVERVIEW
5-Amino-1MQ, also called 5-amino-1-methylquinolinium, is not a peptide. It is an experimental small molecule that inhibits the enzyme NNMT. Researchers study NNMT because it links nicotinamide metabolism, methyl-donor balance, adipose tissue, and cellular energy regulation.
RESEARCH CONTEXT
NNMT is highly expressed in certain metabolic tissues and can influence how nicotinamide and methyl groups are used. Blocking NNMT produced striking metabolic effects in mouse obesity models, which drove interest in 5-Amino-1MQ.
MECHANISM & BIOLOGY
NNMT converts nicotinamide to 1-methylnicotinamide using S-adenosylmethionine. Experimental inhibition can alter nicotinamide availability, NAD-related metabolism, methylation balance, adipocyte energetics, and metabolic gene expression.
HUMAN RESEARCH
No robust published human efficacy program has established 5-Amino-1MQ for weight loss, diabetes, energy, or body composition. Human pharmacokinetics and long-term clinical safety remain largely undefined.
PRECLINICAL RESEARCH
Diet-induced obese mouse studies reported reduced weight gain and adipose mass with NNMT inhibition. Later animal work reported improvements in glucose tolerance and insulin sensitivity under specific experimental conditions. Pharmacokinetic methods have been developed in rats.
SAFETY DATA
Animal exposure does not define human safety. Off-target effects, methyl-donor consequences, chronic NNMT inhibition, reproductive safety, and long-term metabolic effects need study. FDA has cited 5-Amino-1MQ as ineligible for specific 503B compounding exemptions because it is not on the applicable bulks list.
EVIDENCE GAPS
The central question is whether the metabolic phenotype seen in mice translates to humans without unacceptable effects on nicotinamide and methylation biology. That has not been established.
RELATED COMPOUNDS / DISTINCTIONS
5-Amino-1MQ targets NNMT. NAD+ is a coenzyme involved directly in redox metabolism. They intersect conceptually through nicotinamide metabolism but are not equivalent and should not be described as doing the same thing.
Back to compound list ↑
Mitochondrial
SS-31 (Elamipretide)
FDA-APPROVED ACTIVE INGREDIENTFDA accelerated approval as Forzinity for Barth syndrome
OVERVIEW
SS-31 is the research name commonly associated with elamipretide, a mitochondria-targeting tetrapeptide. In September 2025, FDA granted accelerated approval to the finished prescription drug Forzinity (elamipretide) to improve muscle strength in certain patients with Barth syndrome.
RESEARCH CONTEXT
Elamipretide is unusual because it targets cardiolipin, a specialized lipid in the inner mitochondrial membrane. That makes it a direct test of whether stabilizing mitochondrial membrane structure and bioenergetics can improve disease-related muscle dysfunction.
MECHANISM & BIOLOGY
Elamipretide binds cardiolipin in the inner mitochondrial membrane. Research links this interaction to cristae organization, electron-transport-chain efficiency, membrane curvature, reactive-oxygen-species handling, and ATP-related bioenergetics.
HUMAN RESEARCH
Clinical development has produced mixed results. MMPOWER-3 in primary mitochondrial myopathy did not meet its primary endpoints at 24 weeks. Barth syndrome studies and additional evidence ultimately supported FDA accelerated approval of Forzinity based on improvement in knee extensor muscle strength, with confirmatory evidence still required.
PRECLINICAL RESEARCH
Extensive animal and cellular work demonstrates cardiolipin binding and effects on mitochondrial structure, oxidative stress, and bioenergetics across multiple disease models.
SAFETY DATA
The FDA-approved Forzinity label provides the best characterized safety information for the approved finished product and population. Injection-site reactions are prominent. Approval under the accelerated pathway means continued approval may depend on confirmatory demonstration of clinical benefit.
EVIDENCE GAPS
Results in Barth syndrome do not prove benefit for general fatigue, athletic performance, healthy aging, or other mitochondrial conditions. Research material labeled “SS-31” is not automatically equivalent to FDA-approved Forzinity.
RELATED COMPOUNDS / DISTINCTIONS
MOTS-C is an endogenous mitochondrial-derived signaling peptide. Elamipretide is a synthetic cardiolipin-binding drug. NAD+ is a metabolic coenzyme. All relate to mitochondrial biology through different mechanisms.
Back to compound list ↑
Metabolic
Cagrilintide
CLINICAL DEVELOPMENTInvestigational amylin analogue · Not FDA-approved
OVERVIEW
Cagrilintide is a long-acting amylin analogue being studied for chronic weight management. Amylin is a hormone involved in satiety and food intake. Human trials show meaningful weight reduction, but cagrilintide remains investigational.
RESEARCH CONTEXT
Cagrilintide approaches weight regulation through amylin signaling rather than the GLP-1, GIP, or glucagon pathways. This makes it scientifically interesting both alone and in combination with incretin-based medicines.
MECHANISM & BIOLOGY
Cagrilintide acts through amylin and calcitonin receptor systems in the brain. Amylin signaling contributes to satiation, meal-size regulation, and reduced food intake. Its receptor pharmacology differs from GLP-1 receptor agonists.
HUMAN RESEARCH
A randomized Phase 2 dose-finding trial in adults with overweight or obesity reported dose-dependent mean weight reductions of roughly 6% to 11% over 26 weeks across studied cagrilintide doses. Gastrointestinal effects were common. Combination development with semaglutide has progressed into Phase 3 programs.
PRECLINICAL RESEARCH
Animal and receptor studies support central amylin-receptor signaling as an important driver of cagrilintide-related reductions in food intake and body weight.
SAFETY DATA
Human studies commonly report gastrointestinal effects including nausea, constipation, and diarrhea, along with injection-site reactions. Long-term safety and outcomes continue to be studied.
EVIDENCE GAPS
Cagrilintide is not FDA-approved. The safety, efficacy, and dosing of combinations outside controlled clinical-development programs are not established. Evidence from cagrilintide plus semaglutide should not be assumed to establish safety or benefit for cagrilintide combined with retatrutide.
RELATED COMPOUNDS / DISTINCTIONS
Cagrilintide targets amylin-related pathways. Tirzepatide targets GIP and GLP-1. Retatrutide targets GIP, GLP-1, and glucagon. These are distinct mechanisms.
Back to compound list ↑
Endocrine
PT-141 / Bremelanotide
FDA-APPROVED ACTIVE INGREDIENTBremelanotide is FDA-approved in a specific prescription product for a specific indication
OVERVIEW
PT-141 is commonly used as a research name for bremelanotide, a melanocortin receptor agonist. An FDA-approved prescription product containing bremelanotide exists for acquired, generalized hypoactive sexual desire disorder in certain premenopausal women.
RESEARCH CONTEXT
Bremelanotide is unusual because its clinically relevant effects are mediated through central melanocortin signaling rather than directly supplying a sex hormone or acting as a conventional vasodilator.
MECHANISM & BIOLOGY
Bremelanotide is a melanocortin receptor agonist with activity at several melanocortin receptor subtypes. The precise pathway responsible for its clinical effect on sexual desire is not fully established.
HUMAN RESEARCH
Randomized clinical development supported FDA approval of the branded finished drug Vyleesi for a narrowly defined indication in premenopausal women. Approval does not establish treatment of low libido from every cause, male sexual dysfunction, menopause symptoms, or performance enhancement.
PRECLINICAL RESEARCH
Melanocortin-system research and animal studies contributed to development of bremelanotide and to understanding central pathways involved in sexual behavior.
SAFETY DATA
The FDA-approved product labeling includes nausea, flushing, headache, injection-site reactions, and transient increases in blood pressure with reductions in heart rate. It is contraindicated in uncontrolled hypertension or known cardiovascular disease.
EVIDENCE GAPS
Evidence and labeling for the FDA-approved finished product should not be transferred automatically to independently sourced research material, other formulations, other populations, or other indications.
RELATED COMPOUNDS / DISTINCTIONS
PT-141/bremelanotide acts through melanocortin signaling. Kisspeptin acts upstream in the reproductive hormone axis through KISS1R and GnRH signaling. They are not interchangeable.
Back to compound list ↑
Endocrine
Kisspeptin
HUMAN RESEARCHInvestigational reproductive neuropeptide · Not FDA-approved as a peptide drug
OVERVIEW
Kisspeptin is a naturally occurring signaling peptide that sits near the top of the reproductive hormone axis. In humans it activates GnRH signaling, which then influences LH, FSH, and downstream gonadal hormone production.
RESEARCH CONTEXT
Kisspeptin gives researchers a way to study and potentially manipulate the reproductive axis upstream of the pituitary and gonads. Research includes fertility, hypothalamic amenorrhea, reproductive hormone physiology, and psychosexual biology.
MECHANISM & BIOLOGY
Kisspeptin binds KISS1R on GnRH neurons. GnRH then stimulates pituitary release of LH and FSH. The response depends on sex, hormonal environment, dose, route, and administration pattern. Repeated exposure can produce desensitization under some regimens.
HUMAN RESEARCH
Controlled human studies show robust stimulation of LH and other reproductive hormones. Studies in women with hypothalamic amenorrhea and in healthy men and women demonstrate biologic activity, while newer work continues to examine different routes and schedules.
PRECLINICAL RESEARCH
Animal research established kisspeptin as a central regulator of puberty, fertility, GnRH pulsatility, and reproductive feedback before extensive human physiology studies followed.
SAFETY DATA
Short controlled studies have generally characterized acute physiologic responses, but long-term safety for chronic use is not established. Administration pattern matters because tachyphylaxis or desensitization has been observed in some studies.
EVIDENCE GAPS
Kisspeptin is not an established treatment for menopause symptoms, low testosterone, infertility in general, or sexual dysfunction outside specific research settings. Effects vary substantially with reproductive physiology and administration pattern.
RELATED COMPOUNDS / DISTINCTIONS
Kisspeptin influences the hypothalamic-pituitary-gonadal axis. PT-141/bremelanotide primarily targets melanocortin signaling related to sexual desire. Testosterone or estrogen directly replace downstream sex hormones.
Back to compound list ↑
Formulation Research
Super Human Blend (SHB)
INGREDIENT-LEVEL EVIDENCEMulti-ingredient formulation · Blend itself not clinically validated
OVERVIEW
Super Human Blend is a multi-ingredient formulation rather than a single peptide. The listed formulation contains amino acids and related compounds including L-arginine, L-ornithine, L-citrulline, L-lysine, L-glutamine, L-proline, L-taurine, L-carnitine, and N-acetylcysteine. Evidence must be evaluated ingredient by ingredient.
RESEARCH CONTEXT
The ingredients span nitric-oxide biology, amino-acid metabolism, exercise physiology, carnitine-dependent fatty-acid transport, antioxidant pathways, and general nutritional biochemistry. Combining plausible ingredients does not prove that the finished blend improves performance or recovery.
MECHANISM & BIOLOGY
Arginine and citrulline participate in nitric-oxide-related pathways. Carnitine participates in mitochondrial fatty-acid transport. NAC supplies cysteine used in glutathione synthesis. Other amino acids contribute to protein metabolism and diverse cellular functions. The pharmacology of the complete formulation as a combined injectable product has not been established in controlled trials.
HUMAN RESEARCH
Individual ingredients have varying amounts of human nutrition and exercise research, often using oral formulations and different doses. Those studies do not validate the specific combined formulation, route, concentration, or claimed performance effects of SHB.
PRECLINICAL RESEARCH
Mechanistic evidence exists for individual components across vascular, mitochondrial, antioxidant, and metabolic pathways. There is no strong evidence establishing synergy of the complete blend.
SAFETY DATA
Safety depends on formulation, route, concentration, sterility, ingredient quality, individual health conditions, and interactions. Evidence from oral supplements should not be assumed to establish injectable safety.
EVIDENCE GAPS
There is no established clinical protocol, proven performance advantage, validated synergy, or standardized safety profile for the complete SHB formulation.
RELATED COMPOUNDS / DISTINCTIONS
SHB is a formulation built from amino acids and related compounds. It is not equivalent to a peptide hormone, anabolic steroid, HGH, or a clinically validated pre-workout medicine.
Back to compound list ↑
Cellular / Redox Biology
Glutathione
ESTABLISHED BIOLOGY · ROUTE-SPECIFIC EVIDENCEEndogenous tripeptide · Not an FDA-approved injectable drug
OVERVIEW
Glutathione, commonly abbreviated GSH in its reduced form, is an endogenous tripeptide composed of glutamate, cysteine, and glycine. It is a central intracellular redox buffer and participates in antioxidant defense, electrophile conjugation, xenobiotic metabolism, protein thiol regulation, and cellular redox signaling.
RESEARCH CONTEXT
Glutathione is fundamental to normal cell biology. Research focuses on the balance between reduced glutathione (GSH) and oxidized glutathione (GSSG), glutathione synthesis and recycling, glutathione-dependent enzymes, oxidative stress, mitochondrial function, detoxification pathways, and changes in glutathione homeostasis during disease.
MECHANISM & BIOLOGY
GSH donates reducing equivalents to glutathione peroxidases during peroxide reduction and is regenerated from GSSG by glutathione reductase using NADPH. Glutathione S-transferases catalyze conjugation of GSH to electrophilic compounds. Cellular synthesis occurs through sequential actions of glutamate-cysteine ligase and glutathione synthetase. The cysteine thiol group is responsible for much of glutathione’s redox chemistry.
HUMAN RESEARCH
Glutathione has been measured and studied extensively in humans as an endogenous metabolite and biomarker. Clinical research has evaluated oral, inhaled, intravenous, and other routes in different settings, but findings, exposure, and clinical relevance vary substantially by formulation, route, population, and endpoint. Evidence for normal glutathione biology should not be treated as evidence for any specific administered formulation or disease indication.
PRECLINICAL RESEARCH
Cell and animal research has characterized glutathione synthesis, recycling, compartmentalization, oxidative-stress responses, mitochondrial redox biology, drug metabolism, and glutathione-dependent enzyme systems. These models provide extensive mechanistic information, while therapeutic translation depends on route, bioavailability, formulation, and clinical context.
SAFETY DATA
Safety depends strongly on route and product quality. FDA has reported adverse events involving compounded injectable glutathione associated with inappropriate dietary-supplement-grade material and excessive bacterial endotoxin. In August 2026 FDA reported at least 30 patients with adverse events following IV glutathione alone or with other ingredients and emphasized that dietary-supplement-grade ingredients are not appropriate for injectable drugs.
EVIDENCE GAPS
Glutathione biology is well established, but this does not establish the safety or effectiveness of unapproved injectable formulations. Important distinctions include endogenous GSH versus administered GSH, reduced versus oxidized forms, route-specific pharmacokinetics, formulation quality, sterility, and the clinical endpoint being studied.
RELATED COMPOUNDS / DISTINCTIONS
Glutathione is an endogenous tripeptide and redox cofactor. NAD+ is a distinct endogenous redox coenzyme involved in electron transfer and metabolic reactions. They participate in overlapping cellular redox networks but are chemically and functionally different molecules.
Back to compound list ↑
Cognitive
Adamax 1032
UNCHARACTERIZED / INSUFFICIENT PUBLISHED EVIDENCEVendor-defined experimental compound · Not FDA-approved
OVERVIEW
Adamax 1032 is a name used in the research-peptide market for a purported adamantane-modified Semax-related compound with a reported mass near 1032 Da. Unlike Semax, Adamax 1032 does not have an established peer-reviewed biomedical literature under this name, an accepted nonproprietary drug name, or a recognized clinical-development program.
RESEARCH CONTEXT
The compound is discussed because vendors describe it as a modified Semax-related molecule incorporating an adamantane-containing design. Those descriptions propose improved stability or central nervous system exposure, but those propositions have not been established through published pharmacokinetic, receptor, animal, or human studies of Adamax 1032 itself.
MECHANISM & BIOLOGY
No experimentally validated mechanism of action for Adamax 1032 was identified in the indexed biomedical literature reviewed for this library. Mechanistic descriptions circulating online are generally extrapolated from Semax, ACTH-fragment biology, or properties attributed to adamantane-containing molecules. Those extrapolations are not evidence that Adamax 1032 shares the same pharmacology.
HUMAN RESEARCH
No peer-reviewed human clinical studies of Adamax 1032 were identified. No established human pharmacokinetic profile, therapeutic indication, validated dose-response relationship, or controlled safety dataset is available under this compound name.
PRECLINICAL RESEARCH
No peer-reviewed animal or cellular studies specifically characterizing Adamax 1032 were identified. Supplier descriptions and analytical certificates, where available, address marketed material rather than demonstrating biological activity or reproducible pharmacology.
SAFETY DATA
A human safety profile has not been established. Published information is insufficient to characterize acute toxicity, chronic toxicity, immunogenicity, reproductive effects, drug interactions, metabolism, elimination, or route-specific risks. Product identity is an additional issue because materially different structures and molecular masses have circulated under the Adamax name.
EVIDENCE GAPS
Major unknowns include definitive chemical identity, sequence and conjugation site, validated molecular formula, target engagement, receptor pharmacology, blood-brain barrier exposure, half-life, metabolism, dose-response behavior, toxicology, and human effects. The 1032-Da label should be treated as a vendor-defined identifier unless supported by compound-specific analytical characterization.
RELATED COMPOUNDS / DISTINCTIONS
Semax has published preclinical literature and limited regional human research. Adamax 1032 should not be treated as a better-characterized or longer-acting Semax based solely on structural or vendor descriptions because comparative pharmacology has not been established.
Back to compound list ↑